 aTyr Pharma Inc NASDAQ: LIFE is trading significantly higher Tuesday after multiple analyst firms maintained bullish ratings on the stock and raised their respective price targets following the companys announcement that the Phase 1b2a clinical trial of ATYR1923 in pulmonary sarcoidosis met its primary endpoint. HC Wainwright Co. analyst Joseph Pantginis maintained aTyr Pharma with a Buy rating and raised the price target from 13 to 18. 